USPTO Examiner LEE SIN J - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17256989DYNAMIC MAKE-UP PRODUCTDecember 2020April 2025Allow5231YesNo
17133415SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFENDecember 2020March 2022Allow1500NoNo
17126321DUAL PHASE PRODUCTSDecember 2020November 2024Allow4740YesNo
17127186Compressible Cannabinoid Pharmaceutical CompositionDecember 2020January 2022Abandon1320NoNo
16972304COMPOSITION FOR INFLAMMATORY GASTROINTESTINAL DISORDERSDecember 2020September 2022Allow2120NoNo
15734147AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREADecember 2020June 2024Allow4220YesNo
17059790INJECTABLE THERMORESPONSIVE HYDROGELS AS A COMBINATORY MODALITY FOR CONTROLLED DRUG DELIVERY, BIOMATERIAL IMPLANT AND 3D PRINTING BIOINKNovember 2020April 2025Allow5260YesNo
17100677COMPOSITION AND THERAPY FOR TREATMENT OF GAG REFLEXESNovember 2020July 2021Abandon810YesNo
16951335GEL COMPOSITIONS FOR MITIGATION OF BURN INJURIES, KITS CONTAINING THE GEL COMPOSITIONS, AND ASSOCIATED METHODSNovember 2020December 2024Allow4921NoNo
17053705Anti-Dandruff CompositionNovember 2020August 2023Allow3331NoNo
17081827COSMETIC COMPOSITION FOR SKIN BARRIER STRENGTHENING OR MOISTURIZING COMPRISING FERMENTED RICE EXTRACTS, PINEAPPLE EXTRACTS, AND GLYCERYL GLUCOSIDE MIXTUREOctober 2020May 2022Abandon1910NoNo
17050470LIQUID ORAL PHARMACEUTICAL DOSAGE FORMOctober 2020April 2022Allow1810NoNo
17068683METHOD OF INCREASING DURABILITY OF OIL-IN-WATER EMULSION MAKEUPOctober 2020November 2022Abandon2520NoNo
17038928COSMETIC COMPOSITIONS COMPRISING 4-HYDROXYACETOPHENONESeptember 2020June 2025Allow5770YesNo
17039093DEO EMULSION FOR AEROSOLS, DEODORANT COMPRISING THE SAME AND USE OF THE DEODORANTSeptember 2020July 2022Allow2120NoNo
17042555INTRAVAGINAL FORMULATIONSeptember 2020August 2023Allow3440NoNo
17031560DEO EMULSION FOR AEROSOLS WITH REDUCED STAIN PROBLEM, DEODORANT COMPRISING THE SAME AND USE OF THE DEODORANTSeptember 2020January 2022Allow1610NoNo
16975543OXYGEN GENERATING FACE MASKSAugust 2020November 2022Abandon2720NoNo
16975302HARD-PRESSED SCORED SPLITTABLE MARIJUANA TABLETSAugust 2020August 2024Abandon4801NoNo
16971509COMPOSITIONS FOR PROVIDING SKIN CARE BENEFITS AND METHODS OF USEAugust 2020October 2022Abandon2610NoNo
16967940TREATMENT OF GRAM-NEGATIVE FOLLICULITIS OR AN INFLAMMATION THEREOF WITH BESIFLOXACINAugust 2020December 2022Abandon2910NoNo
16915479VISIBLE LIGHT-CURABLE WATER-SOLUBLE CHITOSAN DERIVATIVE, CHITOSAN HYDROGEL, AND PREPARATION METHOD THEREFORJune 2020August 2020Allow200YesNo
16913258METHOD FOR LYOPHILIZING EXOSOMEJune 2020March 2022Allow2110NoNo
16954833STORAGE STABLE MIXTURESJune 2020September 2024Allow5120NoNo
16771519Antiperspirant / Deodorant Compositions Including Biodegradable Amino Carboxylates and Methods for the SameJune 2020October 2022Allow2840NoNo
16891586COMPOSITIONS COMPRISING INDIGO AND/OR AN INDIGO DERIVATIVE AND METHODS OF USE THEREOFJune 2020July 2022Abandon2501NoNo
16892213METHODS AND COMPOSITION FOR IMPROVED ANTISEPSISJune 2020March 2022Abandon2110NoNo
16884366Taurine and Aloe Synergistic Anti-Irritant Compositions and MethodsMay 2020July 2021Allow1430NoNo
16875683OIL-SOLUBLE DRUG CONTAINING COMPOSITIONS AND METHODS OF USE THEREOFMay 2020October 2023Abandon4131NoNo
16874300CANNABIDIOL NANOCRYSTAL COMPOSITIONSMay 2020June 2023Abandon3740NoNo
16762943ORGANOSILICON ANTIMICROBIAL SOLUTION, ORGANOSILICON ANTIMICROBIAL AGENT, ANTIMICROBIAL GLASS, PREPARATION METHOD THEREFOR AND USE THEREOFMay 2020October 2021Allow1720NoNo
16762860HYDROGEL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF PEDIATRIC GROWTH PLATE INJURIESMay 2020April 2024Abandon4731NoNo
16762138A THERMO-RESPONSIVE HYDROGEL FOR INTRATUMORAL ADMINISTRATION AS A TREATMENT IN SOLID TUMOR CANCERSMay 2020August 2022Allow2730NoNo
16761357EMULSION COMPRISING AN ANIONIC ACRYLIC COPOLYMER AND A LIPOPHILIC POLYMERMay 2020August 2022Allow2720NoNo
16865183COMPOSITIONS COMPRISING INDIGO AND/OR AN INDIGO DERIVATIVE AND METHODS OF USE THEREOFMay 2020June 2022Abandon2611NoNo
16760191COSMETIC EMULSION CONTAINING A GEMINI SURFACTANT AND A LIPOPHILIC POLYMERApril 2020January 2025Allow5760YesNo
16759925METHOD FOR THE FORMULATION OF OIL-SOLUBLE SUBSTANCES, AND POWDERS OBTAINABLE THEREOFApril 2020December 2023Allow4330NoNo
16758434Personal Care Compositions Including Naringin:zinc Complexes and Methods for the SameApril 2020June 2021Allow1310NoNo
16755818LIQUID COSMETIC WITH AGAR SHELL CAPSULEApril 2020June 2022Allow2621NoNo
16753726RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONSApril 2020April 2022Abandon2501NoNo
16651403DELIVERY SYSTEMS FOR PEROXIDE COMPOUNDS AND THEIR APPLICATIONSMarch 2020March 2023Allow3640NoNo
16804856HIGH POLYOL WASH COMPOSITIONFebruary 2020November 2021Abandon2010NoNo
16788563THERAPEUTIC COMPOSITION AND METHODSFebruary 2020September 2022Allow3221NoYes
16777949CELLULOSE COMPOSITIONJanuary 2020March 2024Allow5040YesNo
16635068COSMETICJanuary 2020May 2022Allow2720YesNo
16775253PHOSPHOLIPID COMPOUNDS AND FORMULATIONSJanuary 2020October 2020Allow910YesNo
16744497METHODS OF MAKING POLYTETRAFLUOROETHYLENE/POLYMER COMPOSITES AND USES THEREOFJanuary 2020August 2024Allow5541NoNo
16631208Efficacy of a Gastro-Retentive Bile Acid Sequestrant Dosage FormJanuary 2020December 2023Abandon4701NoNo
16742675System, Method and Compositions for Treating Age-Related Illnesses and ConditionsJanuary 2020March 2023Abandon3810NoNo
16629639SUNSCREEN AGENT WITH A PROTECTION AGAINST TEXTILE SPOTTING DUE TO 4-(TERT.-BUTYL)-4'-METHOXYDIBENZOYLMETHANEJanuary 2020December 2021Abandon2310NoNo
16720223PH-Sensitive Starch-Based Microcapsule and Its Preparation MethodDecember 2019June 2021Allow1810NoNo
16623834TOPICAL COMPOSITIONS AND METHODS OF USING THE SAMEDecember 2019October 2021Abandon2220NoNo
16715223TWO-COMPONENT HAIR CARE AGENT WITH COLOR INDICATOR FOR THE IDENTIFICATION OF THE OPTIMUM PH VALUE, METHOD OF APPLYING THE SAME AND USING THE SAMEDecember 2019December 2022Abandon3640YesNo
16622742NASAL COMPOSITIONDecember 2019November 2021Abandon2310NoNo
16708326PROCESS FOR INFUSING A TERPENE SOLUTION INTO A STORAGE CONTAINER THAT STORES CANNABISDecember 2019February 2023Abandon3810NoNo
16615434LIQUID CLEANSING COMPOSITIONNovember 2019January 2021Allow1410NoNo
16614330SUNSCREEN COMPOSITIONNovember 2019April 2025Allow6080YesNo
16685330HAIR OILS FOR CONDITIONING KERATIN FIBRESNovember 2019November 2021Allow2440NoNo
16684073COMBINATION TREATMENT OF BACTERIAL INFECTIONNovember 2019February 2023Allow3940NoNo
16670163METHODS OF TREATMENT USING NIMODIPINE PARENTERAL FORMULATIONSOctober 2019December 2020Abandon1310NoNo
16669233COMPOSITION COMPRISING 2-ETHYL-1,3-HEXANEDIOL FOR USE IN A DEODORANT SPRAY OR ANTIPERSPIRANT SPRAYOctober 2019February 2022Abandon2730NoNo
16668580COLOR- AND CLARITY-STABLE NATURAL MICELLAR WATEROctober 2019February 2025Allow6080YesNo
16609346Cosmetic Compositions for Skin Health and Methods of Using SameOctober 2019May 2022Allow3130NoNo
16665344Solid Bar ShampooOctober 2019August 2021Abandon2220YesNo
16606804LOW VISCOSITY, HIGH POLYOL SELF-FOAMING COMPOSITIONOctober 2019April 2025Allow6040NoYes
16606936IODINE COMPOSITIONSOctober 2019November 2021Allow2420NoNo
16656180GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOROctober 2019July 2023Abandon4521NoNo
16604473PERSONAL CARE PRODUCTSOctober 2019October 2022Allow3720YesNo
16604019METHOD FOR REMOVING KERATOTIC PLUGSOctober 2019April 2022Allow3020YesNo
16500932NANOFIBERS COMPRISING FIBROIN AS WELL AS SYSTEM COMPRISING HYDROGEL AND SAID NANOFIBERSOctober 2019March 2023Abandon4111NoNo
16498943Pharmaceutical formulationSeptember 2019September 2022Allow3620YesNo
16578040Gel Texturizer Base for CosmeticsSeptember 2019May 2022Abandon3211NoNo
16492903COMPLEXES FOR TREATING SENSITIVITYSeptember 2019January 2025Allow6041NoNo
16560084Eye Drops for Treatment of Irritation Not Due to InfectionSeptember 2019February 2021Allow1710NoNo
16491030PHARMACEUTICAL FORMULATIONS OF PHLOROGLUCINOL AND TRIMETHYLPHLOROGLUCINOLSeptember 2019October 2023Abandon4941NoNo
16554134OPHTHALMIC FORMULATIONS, PROCESS FOR PREPARING THE SAME AND METHOD FOR ADMINISTERING THE SAMEAugust 2019January 2022Abandon2930NoNo
16485934WATER-SOLUBLE NANOCERIA AND METHODS OF MAKING AND USING THE SAMEAugust 2019October 2021Abandon2730YesNo
16537823THERAPEUTIC COMPOSITION AND METHODSAugust 2019September 2022Allow3821YesYes
16484430TOPICAL FORMULATIONS AND METHODSAugust 2019April 2023Allow4540YesNo
16484408A HAIR CONDITIONING COMPOSITIONAugust 2019April 2022Abandon3240YesNo
16481613ADMINISTRATION REGIMEN FOR A PHARMACEUTICAL PATCH COMPRISING LIDOCAINE AND DICLOFENACJuly 2019June 2023Abandon4650YesNo
16525120Photoresist and MethodJuly 2019October 2019Allow310NoNo
16517423RESPIRATORY TRACT DELIVERY OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR FOR TREATMENT OF PARKINSON'S DISEASEJuly 2019July 2022Allow3650YesNo
16478883Biochloride Generation and MethodsJuly 2019September 2021Abandon2620NoNo
16476633MICROCAPSULES COMPRISING CINMETHYLN IN THE CORE AND A POLYUREA DERIVED FROM DIPHENYLMETHANE DIISOCYANATE OR AN OLIGOMER THEREOFJuly 2019April 2025Allow6071NoNo
16475283METHODS OF REMOVING SPORESJuly 2019January 2025Abandon6080NoNo
16474096WATER-IN-OIL EMULSION COSMETICJune 2019October 2022Allow4050NoNo
16474393PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING THE SAMEJune 2019September 2021Allow2740YesNo
16474083METHODS AND DEVICES FOR TREATING LEVODOPA INDUCED DYSKINESIAJune 2019May 2021Abandon2301NoNo
16453813COMPOSITION COMPRISING A CROSSLINKED HYALURONIC ACID (HA) IN COMBINATION WITH A LOW-MOLECULAR HA AND/OR AN AGENT STIMULATING ENDOGENOUS HA SYNTHESISJune 2019September 2021Allow2730YesNo
16473693Substituted Heterocycle Fused Gamma-Carbolines for Treatment of Central Nervous System DisordersJune 2019November 2020Allow1710YesNo
16453798MICRO- OR NANOPARTICULAR MULTILAMELLAR VESICLES, COMPOSITIONS COMPRISING THE SAME AND METHOD FOR THEIR USE IN SKIN CAREJune 2019July 2021Abandon2520NoNo
16453230METHODS OF PROMOTING THE HEALING OF CONCAVE WOUNDSJune 2019March 2022Abandon3331NoNo
16446634ORAL pH INDEPENDENT DOSAGE FORMULATION FOR TREATING NEURODEGENERATIVE DISORDERSJune 2019November 2020Allow1711NoNo
16470873METHOD FOR PRODUCING BEADSJune 2019March 2023Abandon4540NoNo
16470513PERSONAL CARE COMPOSITIONS WITH CYSTINEJune 2019November 2021Allow2930NoYes
16469863THERAPEUTIC AGENT FOR ONYCHOMYCOSISJune 2019October 2020Abandon1610NoNo
16469763OIL-IN-WATER TYPE COMPOSITIONJune 2019June 2022Abandon3640NoNo
16427274SKIN LIGHTENING COMPOSITIONS AND METHODSMay 2019September 2020Allow1620YesNo
16464643Ultrastable Gold Nanoparticles For Drug Delivery Applications And Synthesis ThereofMay 2019October 2023Abandon5351NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEE, SIN J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
2
Examiner Affirmed
1
(50.0%)
Examiner Reversed
1
(50.0%)
Reversal Percentile
69.8%
Higher than average

What This Means

With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
11
Allowed After Appeal Filing
2
(18.2%)
Not Allowed After Appeal Filing
9
(81.8%)
Filing Benefit Percentile
23.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner LEE, SIN J - Prosecution Strategy Guide

Executive Summary

Examiner LEE, SIN J works in Art Unit 1613 and has examined 261 patent applications in our dataset. With an allowance rate of 65.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner LEE, SIN J's allowance rate of 65.9% places them in the 28% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by LEE, SIN J receive 2.60 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LEE, SIN J is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +27.9% benefit to allowance rate for applications examined by LEE, SIN J. This interview benefit is in the 74% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.1% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 44.1% of cases where such amendments are filed. This entry rate is in the 68% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 73.2% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.1% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

    Relevant MPEP Sections for Prosecution Strategy

    • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
    • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
    • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
    • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
    • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
    • MPEP § 1214.07: Reopening prosecution after appeal

    Important Disclaimer

    Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

    No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

    Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

    Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.